WASHINGTON - US biotech firm Moderna said Wednesday that doses of its new COVID-19 vaccine candidate aimed at the South African coronavirus variant had been shipped to the US National Institutes of Health for testing.
That means people who were infected with the classic strain are more susceptible to reinfection, and research has also shown the variant has partly reduced the protection of the current generation of vaccines. Another idea is that people could receive a third dose of the classic vaccine to raise their overall immunity.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:
Ey, we have a chance in 2022!